Diamyd Medical AB (publ) (STO:DMYD.B)

Diamyd Medical AB Cash Flow Statement

Financials in millions SEK. Fiscal year is September - August.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	May 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020
Net Income	-174.65	-151.85	-116.07	-103.52	60.05	9.71
Depreciation & Amortization	6.33	5.58	4.87	4.38	0.78	0.15
Asset Writedown & Restructuring Costs	5.41	5.41	-	-	-	-
Other Operating Activities	-10.42	3.77	1.69	-11.61	-145.64	0.04
Change in Accounts Receivable	0.14	-13.5	0.07	10.1	-19.57	1.13
Change in Other Net Operating Assets	21.41	21.41	-1.51	7.43	-5.1	5.85
Operating Cash Flow	-162.9	-129.18	-110.96	-93.22	-109.47	16.88
Capital Expenditures	-8.45	-8.03	-11.44	-34.65	-4.23	-1.98
Investment in Securities	46.6	-19.97	39.84	-39.91	-7.66	6.8
Other Investing Activities	0.18	-0	-	6.65	144.41	-
Investing Cash Flow	38.33	-27.99	28.4	-76.72	132.53	4.82
Issuance of Common Stock	315.39	135.21	75.27	150	60	-
Other Financing Activities	1.17	7.08	11.27	-7.85	-3.28	-
Financing Cash Flow	316.56	142.28	86.54	142.16	56.72	-
Foreign Exchange Rate Adjustments	4.43	0.12	3.79	8.17	1.22	-0.04
Miscellaneous Cash Flow Adjustments	-0.18	-	-	-	-0	-0
Net Cash Flow	196.23	-14.78	7.77	-19.62	81.01	21.67
Free Cash Flow	-171.36	-137.21	-122.4	-127.87	-113.69	14.9
Free Cash Flow Margin	-132833.33%	-105543.08%	-22418.32%	-28165.42%	-44937.94%	4369.80%
Free Cash Flow Per Share	-1.66	-1.45	-1.56	-1.67	-1.63	0.21
Cash Interest Paid	-	0.01	0	0.25	0.07	0.03
Levered Free Cash Flow	-111.95	-91.21	-80.42	-82.04	-82.18	-16.07
Unlevered Free Cash Flow	-110.94	-91.2	-80.42	-81.88	-81.9	-15.74
Change in Working Capital	10.43	7.91	-1.45	17.52	-24.66	6.99

Updated May 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.